TY - JOUR
T1 - Association of Frailty With Treatment Selection and Long-Term Outcomes Among Patients With Chronic Limb-Threatening Ischemia
AU - Butala, Neel M.
AU - Raja, Aishwarya
AU - Xu, Jiaman
AU - Strom, Jordan B.
AU - Schermerhorn, Marc
AU - Beckman, Joshua A.
AU - Shishehbor, Mehdi H.
AU - Shen, Changyu
AU - Yeh, Robert W.
AU - Secemsky, Eric A.
N1 - Funding Information:
Dr Butala is funded by the John S. LaDue Memorial Fellowship at Harvard Medical School, Boston, MA and reports consulting fees and ownership interest in HiLabs, outside the submitted work. Dr Secemsky receives grants from AstraZeneca, BD Bard, Boston Scientific, Cook Medical, CSI, Medtronic, Philips, and UCSF. He consults for CSI, Medtronic, and Philips and is on the speaking bureau of BD Bard, Cook Medical and Medtronic, outside the submitted work. Dr Schermerhorn has received support from Abbott, Cook Medical, Endologix, Medtronic, and Philips, outside the submitted work. Dr Beckman has served as a consultant for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Novo Nordisk, and Sanofi; and has served on the Data Safety and Monitoring Board of Bayer and Novartis, outside the submitted work. Dr Shishehbor has served on the Scientific Advisory Boards of Medtronic, Abbott Vascular, Phillips, Terumo, and Boston Scientific, outside the submitted work. Dr Yeh reports additional grant support from Abiomed, Astra Zeneca, and Boston Scientific and consulting fees from Abbott, Boston Scientific, Medtronic, and Teleflex, outside the submitted work. The remaining authors have no disclosures to report.
Publisher Copyright:
© 2021 The Authors.
PY - 2021/12/21
Y1 - 2021/12/21
N2 - BACKGROUND: The optimal treatment strategy for patients with chronic limb-threatening ischemia (CLTI) is often unclear. Frailty has emerged as an important factor that can identify patients at greater risk of poor outcomes and guide treatment selection, but few studies have explored its utility among the CLTI population. We examine the association of a health record-based frailty measure with treatment choice and long-term outcomes among patients hospitalized with CLTI. METHODS AND RESULTS: We included patients aged >65 years hospitalized with CLTI in the Medicare Provider Analysis and Review data set between October 1, 2009 and September 30, 2015. The primary exposure was frailty, defined by the Claims-based Frailty Indicator. Baseline frailty status and revascularization choice were examined using logistic regression. Cox proportional hazards regression was used to determine the association between frailty and death or amputation, stratifying by treatment strategy. Of 85 060 patients, 35 484 (42%) were classified as frail. Frail patients had lower likelihood of revascularization (adjusted odds ratio [OR], 0.78; 95% CI, 0.75‒0.82). Among those revascularized, frailty was associated with lower likelihood of surgical versus endovascular treatment (adjusted OR, 0.76; CI, 0.72‒0.81). Frail patients experienced increased risk of amputation or death, regardless of revascularization status (revascularized: adjusted hazard ratio [HR], 1.34; CI, 1.30‒ 1.38; non-revascularized: adjusted HR, 1.22; CI, 1.17‒1.27). Among those revascularized, frailty was independently associated with amputation or death irrespective of revascularization strategy (surgical: adjusted HR, 1.36; CI, 1.31‒1.42; endovascular: aHR, 1.29; CI, 1.243‒1.35). CONCLUSIONS: Among patients hospitalized with CLTI, frailty is an important independent predictor of revascularization strategy and longitudinal adverse outcomes.
AB - BACKGROUND: The optimal treatment strategy for patients with chronic limb-threatening ischemia (CLTI) is often unclear. Frailty has emerged as an important factor that can identify patients at greater risk of poor outcomes and guide treatment selection, but few studies have explored its utility among the CLTI population. We examine the association of a health record-based frailty measure with treatment choice and long-term outcomes among patients hospitalized with CLTI. METHODS AND RESULTS: We included patients aged >65 years hospitalized with CLTI in the Medicare Provider Analysis and Review data set between October 1, 2009 and September 30, 2015. The primary exposure was frailty, defined by the Claims-based Frailty Indicator. Baseline frailty status and revascularization choice were examined using logistic regression. Cox proportional hazards regression was used to determine the association between frailty and death or amputation, stratifying by treatment strategy. Of 85 060 patients, 35 484 (42%) were classified as frail. Frail patients had lower likelihood of revascularization (adjusted odds ratio [OR], 0.78; 95% CI, 0.75‒0.82). Among those revascularized, frailty was associated with lower likelihood of surgical versus endovascular treatment (adjusted OR, 0.76; CI, 0.72‒0.81). Frail patients experienced increased risk of amputation or death, regardless of revascularization status (revascularized: adjusted hazard ratio [HR], 1.34; CI, 1.30‒ 1.38; non-revascularized: adjusted HR, 1.22; CI, 1.17‒1.27). Among those revascularized, frailty was independently associated with amputation or death irrespective of revascularization strategy (surgical: adjusted HR, 1.36; CI, 1.31‒1.42; endovascular: aHR, 1.29; CI, 1.243‒1.35). CONCLUSIONS: Among patients hospitalized with CLTI, frailty is an important independent predictor of revascularization strategy and longitudinal adverse outcomes.
KW - chronic limb-threatening ischemia
KW - frailty
KW - outcomes
UR - http://www.scopus.com/inward/record.url?scp=85122845690&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122845690&partnerID=8YFLogxK
U2 - 10.1161/JAHA.121.023138
DO - 10.1161/JAHA.121.023138
M3 - Article
C2 - 34913364
AN - SCOPUS:85122845690
SN - 2047-9980
VL - 10
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 24
M1 - e023138
ER -